Novel targets and biomarkers in mesothelioma
Abiraterone: a step forward in the treatment of prostate cancer
Highlighting problems in personalized medicine
Clinical implications of CTCs in prostate cancer – are they the best thing to measure?
Design and results of Phase III FALCON trial of fulvestrant for advanced breast cancer